Results 81 to 90 of about 15,884 (195)
Then and now: the progress in hepatitis B treatment over the past 20 years. [PDF]
, 2014 The ultimate goals of treating chronic hepatitis B (CHB) is prevention of hepatocellular carcinoma (HCC) and hepatic decompensation. Since the advent of effective antiviral drugs that appeared during the past two decades, considerable advances have been ...
Halegoua-De Marzio, Dina, Hann, Hie-Won
core +2 more sources
Journal of Medical Virology, Volume 98, Issue 3, March 2026.ABSTRACT Background and Aim Chronic hepatitis B (CHB) affects over 250 million people globally and is a major contributor to liver complications, including cirrhosis and hepatocellular carcinoma (HCC). Though antiviral therapies suppress HBV, the rising prevalence of metabolic‐associated steatotic liver disease (MASLD) poses new challenges.
Sheng‐Jie Shiue +12 more
wiley +1 more source
Antiviral treatment for chronic hepatitis B virus infection--immune modulation or viral suppression? [PDF]
, 2006 The availability of nucleoside analogues has broadened treatment options for chronic hepatitis B virus (HBV ) infection. Registered treatment for chronic hepatitis B currently consists of (pegylated) interferon, lamivudine and adefovir,
Buster, E.H.C.J. (Erik) +1 more
core +5 more sources
Alimentary Pharmacology &Therapeutics, Volume 63, Issue 5, Page 592-602, March 2026.This meta‐analysis demonstrates a significantly lower risk for HBV reactivation on rituximab if anti‐HBs is > 100 iU/L (3.5%, CI: 1.8%–6.9%) vs. anti‐HBs between 10 and 100 iU/L (13.8%, CI: 8.8%–20.8%) and anti‐HBs negative (27.3%, CI: 20.0%–36.0%). Thus, if anti‐HBs titer is > 10 iU/L, monitoring could be considered.
Shiva Poola +4 more
wiley +1 more source
Effect and safety analysis of Yiqi Yangxue Jiedu decoction combined with entecavir in the treatment of male patients with decompensated hepatitis B cirrhosis [PDF]
Journal of Men's HealthBackground: This study aimed to evaluate the efficacy and safety of Yiqi Yangxue Jiedu Decoction & Entecavir in male patients with decompensated hepatitis B cirrhosis.
Mingli Jia
doaj +1 more source
Infections in Chronic Lymphocytic Leukemia: Evolving Risks and Prevention Strategies
European Journal of Haematology, Volume 116, Issue 3, Page 204-214, March 2026.ABSTRACT Infections remain a leading cause of morbidity and mortality in patients with chronic lymphocytic leukemia (CLL), reflecting both intrinsic immune dysfunction and therapy‐related immunosuppression. The pathogenesis of immunodeficiency in CLL is multifactorial: neoplastic B cells impair humoral immunity, T cells are functionally exhausted, and ...
Enrica Antonia Martino +10 more
wiley +1 more source
The Saudi Journal of Gastroenterology, 2015 Background/Aims: This study aimed to evaluate the antiviral response and safety of tenofovir (TDF) versus entecavir (ETV) in treatment-naïve CHB patients. Patients and Methods: We performed a retrospective cohort study of treatment-naive CHB patients who
Hyung Min Yu +11 more
doaj +1 more source
Modeling host interactions with hepatitis B virus using primary and induced pluripotent stem cell-derived hepatocellular systems [PDF]
, 2014 Hepatitis B virus (HBV) chronically infects 400 million people worldwide and is a leading driver of end-stage liver disease and liver cancer. Research into the biology and treatment of HBV requires an in vitro cell-culture system that supports the ...
Bhatia, Sangeeta N +6 more
core +1 more source
Updates in the treatment of chronic hepatitis B [PDF]
, 2008 published_or_final_versio
Fung, J, Lai, CL, Yuen, MF
core
Hepatitis B virus reactivation in breast cancer patients undergoing chemotherapy: A review and meta-analysis of prophylaxis management [PDF]
, 2017 Hepatitis B virus (HBV) reactivation during or after chemotherapy in patients with breast cancer has become a remarkable clinical problem. Prophylactic nucleos(t)ide analogues (NAs) are recommended for patients with breast cancer who are hepatitis B ...
Gong, Chang +6 more
core +2 more sources